Cell Therapy Consulting
Precision Advisory for Cell & Gene Therapy Development
Expert strategic guidance for clinical development, regulatory pathways, and manufacturing — delivered by scientists who have led programs from bench to approval.
Consulting Services
End-to-End Expertise Across the Development Continuum
Clinical Development Strategy
Phase I–III trial design, endpoint selection, and adaptive protocol development for cell therapy programs.
Regulatory Pathway Advisory
FDA, EMA, and global regulatory strategy including IND/CTA preparation and agency meeting support.
Manufacturing & CMC Consulting
Process development, scale-up strategy, and CMC documentation for autologous and allogeneic platforms.
Preclinical Program Design
In vitro and in vivo study design, biomarker strategy, and translational research planning.
Market Access & Reimbursement
Health economics, payer strategy, and value dossier development for advanced therapy medicinal products.
Science-first advisory. No generalists.
Deep domain expertise
Every engagement is led by scientists with direct cell therapy development experience — not generalist consultants.
Regulatory precision
We have navigated FDA and EMA review processes for CAR-T, TCR, and stem cell programs across multiple indications.
Translational rigor
Our methodology bridges preclinical data to clinical strategy, ensuring scientific rationale drives every regulatory decision.
Institutional partnerships
We work exclusively with qualified medical centers, biotech companies, and academic research institutions.
Ready to advance your program?
Schedule a confidential consultation to discuss your cell therapy development challenges.
For qualified medical and research institutions only.